Examining valganciclovir prophylaxis duration among high‐risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort

Abstract
Click on the article title to read more.
Funding Information
  • National Institute of Allergy and Infectious Diseases (K23 HL143050, HHSN272201600019C, HHSN272201600016C, HHSN272201100041C, T32 AI118690‐03)